5 results
Primary objective is to compare all cause discontinuation rates in patients with schizophrenia randomized to either one of the two depot medications (aripiprazole depot or paliperidone palmitate) with patients randomized to either one of the two…
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.
In SPACe 2 STAR, we aim to reach further, we will test whether application of TDM in clinical practice is indeed able to reduce the number/severity of metabolic side effects, while retaining clinical effectiveness in children by means of a…
The main objective of this study is to investigate the feasibility of a larger single-blind, randomized trial focused on (cost) effectiveness and safety of ECT vs. aripiprazole addition in patients with schizophrenia spectrum disorders (SSD)…